Plain-English translation of NCT05158101 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called AlloEx, which contains tiny particles derived from stem cells obtained from umbilical cord tissue. The medication is delivered as a nasal spray over two consecutive days. Researchers want to see if this treatment is safe and whether it can help people recover better after a stroke.
Stroke can cause serious disability, and current recovery options are limited. This medication may help repair brain damage and improve recovery by reducing inflammation and promoting healing in the brain.
You likely qualify if…
You likely don't qualify if…
You will receive the nasal spray treatment on two back-to-back days, with each dose taking just a few minutes. You'll then return for follow-up visits at 1 month, 6 months, 12 months, 24 months, 36 months, and 48 months to check how you're doing and whether the treatment is helping. The study lasts up to 4 years from your treatment date.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Greece
Phase
Safety & dosing
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment target
~15 participants
Started
February 2022
Primary completion
February 2028
Last updated on clinicaltrials.gov in October 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.